-
2024-512195-35-00
5
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
-
2024-519753-11-00
4
Resectable borderline pancreatic adenocarcinoma
-
2024-519894-20-01
5
Adult with an staphylococcal prosthetic joint infection treated with d
-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
-
2025-523670-17-00
5
Systemic lupus erythematosus
-
2025-521865-29-00
4
2026-04-30
moderate-to-severe hidradenitis suppurativa
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2024-517099-39-00
4
2024-11-18
Newly diagnosed transplant ineligible multiple myeloma
-
2023-503920-14-00
5
2024-01-02
Non-Small Cell Lung Cancer (NSCLC)
-
2023-504670-38-00
4
2023-11-17
Extensive disease Small Cell Lung Cancer
-
2024-517337-41-00
5
2026-05-12
Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2024-519208-29-00
4
2026-04-02
Pleural mesothelioma
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2023-506935-14-01
5
2025-06-01
Ischemic stroke
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2023-509806-31-00
4
2025-02-11
Non-Small Cell Lung Cancer
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB